Brought to you by 
Watson acquires Actavis for €4.25bn, becoming third-largest generics company
11 Jun 2021
Executive Summary
After months of speculation, Watson Pharmaceuticals Inc. has paid €4.25bn ($5.6bn) up front for privately held Actavis Group, creating the third-largest generics company in the world behind Teva and Sandoz. The deal includes $5.5bn in cash, the assumption of $132mm in debt, and an earn-out payment of 5.5mm Watson common shares (valued at $373mm) to be issued in 2013 if Actavis meets certain performance targets in 2012.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson acquires Actavis for €4.25bn, becoming third-largest generics company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice